Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits

Jiafen Hu, Nancy Cladel, Karla Balogh, Neil Christensen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

DNA vaccines delivered subcutaneously by gene-gun have generated strong protective and therapeutic immunity in rabbits. Recent studies have shown that peptides delivered by the mucosal routes also stimulate local and systemic immune responses. Since mucosal delivery is easier to administer and more cost-effective when compared to gene-gun delivery, we were interested to learn whether mucosally delivered peptides would prime protective immunity comparable to that of gene-gun-delivered DNA in rabbits. Our newly developed HLA-A2.1 transgenic rabbit model was used to test the hypothesis. We chose an HLA-A2.1 restricted cottontail rabbit papillomavirus (CRPV) E1 epitope (E1/303-311, MLQEKPFQL) for the peptide immunization studies because it provided complete protection when used as a DNA vaccine. Adjuvant has been widely used to boost immunity for vaccines. In this study, three adjuvants reported to be effective for rabbits (TT helper motif, PADRE and CpG2007) were tested with the peptide vaccine. Peptide alone or fused to TT helper or PADRE to create chimeric peptides was delivered by two mucosal routes (ocular and intranasal) together. Partial protection was found in HLA-A2.1 transgenic rabbits when peptide was delivered mucosally in the presence of adjuvant. When a subsequent booster of a half-dose of the corresponding DNA vaccine was delivered, complete protections were achieved. We conclude that mucosal peptide immunization can be combined with a single DNA vaccination to provide strong protective immunity in rabbits.

Original languageEnglish (US)
Pages (from-to)3706-3713
Number of pages8
JournalVaccine
Volume28
Issue number21
DOIs
StatePublished - May 7 2010

Fingerprint

Immunity
immunity
rabbits
genetically modified organisms
peptides
Rabbits
Peptides
DNA Vaccines
Firearms
recombinant vaccines
adjuvants
Cottontail rabbit papillomavirus
Immunization
immunization
Genes
Subunit Vaccines
genes
subunit vaccines
DNA
epitopes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Hu, Jiafen ; Cladel, Nancy ; Balogh, Karla ; Christensen, Neil. / Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits. In: Vaccine. 2010 ; Vol. 28, No. 21. pp. 3706-3713.
@article{2c513ca458c245f0a6945abc047d16c0,
title = "Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits",
abstract = "DNA vaccines delivered subcutaneously by gene-gun have generated strong protective and therapeutic immunity in rabbits. Recent studies have shown that peptides delivered by the mucosal routes also stimulate local and systemic immune responses. Since mucosal delivery is easier to administer and more cost-effective when compared to gene-gun delivery, we were interested to learn whether mucosally delivered peptides would prime protective immunity comparable to that of gene-gun-delivered DNA in rabbits. Our newly developed HLA-A2.1 transgenic rabbit model was used to test the hypothesis. We chose an HLA-A2.1 restricted cottontail rabbit papillomavirus (CRPV) E1 epitope (E1/303-311, MLQEKPFQL) for the peptide immunization studies because it provided complete protection when used as a DNA vaccine. Adjuvant has been widely used to boost immunity for vaccines. In this study, three adjuvants reported to be effective for rabbits (TT helper motif, PADRE and CpG2007) were tested with the peptide vaccine. Peptide alone or fused to TT helper or PADRE to create chimeric peptides was delivered by two mucosal routes (ocular and intranasal) together. Partial protection was found in HLA-A2.1 transgenic rabbits when peptide was delivered mucosally in the presence of adjuvant. When a subsequent booster of a half-dose of the corresponding DNA vaccine was delivered, complete protections were achieved. We conclude that mucosal peptide immunization can be combined with a single DNA vaccination to provide strong protective immunity in rabbits.",
author = "Jiafen Hu and Nancy Cladel and Karla Balogh and Neil Christensen",
year = "2010",
month = "5",
day = "7",
doi = "10.1016/j.vaccine.2010.03.015",
language = "English (US)",
volume = "28",
pages = "3706--3713",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "21",

}

Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits. / Hu, Jiafen; Cladel, Nancy; Balogh, Karla; Christensen, Neil.

In: Vaccine, Vol. 28, No. 21, 07.05.2010, p. 3706-3713.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits

AU - Hu, Jiafen

AU - Cladel, Nancy

AU - Balogh, Karla

AU - Christensen, Neil

PY - 2010/5/7

Y1 - 2010/5/7

N2 - DNA vaccines delivered subcutaneously by gene-gun have generated strong protective and therapeutic immunity in rabbits. Recent studies have shown that peptides delivered by the mucosal routes also stimulate local and systemic immune responses. Since mucosal delivery is easier to administer and more cost-effective when compared to gene-gun delivery, we were interested to learn whether mucosally delivered peptides would prime protective immunity comparable to that of gene-gun-delivered DNA in rabbits. Our newly developed HLA-A2.1 transgenic rabbit model was used to test the hypothesis. We chose an HLA-A2.1 restricted cottontail rabbit papillomavirus (CRPV) E1 epitope (E1/303-311, MLQEKPFQL) for the peptide immunization studies because it provided complete protection when used as a DNA vaccine. Adjuvant has been widely used to boost immunity for vaccines. In this study, three adjuvants reported to be effective for rabbits (TT helper motif, PADRE and CpG2007) were tested with the peptide vaccine. Peptide alone or fused to TT helper or PADRE to create chimeric peptides was delivered by two mucosal routes (ocular and intranasal) together. Partial protection was found in HLA-A2.1 transgenic rabbits when peptide was delivered mucosally in the presence of adjuvant. When a subsequent booster of a half-dose of the corresponding DNA vaccine was delivered, complete protections were achieved. We conclude that mucosal peptide immunization can be combined with a single DNA vaccination to provide strong protective immunity in rabbits.

AB - DNA vaccines delivered subcutaneously by gene-gun have generated strong protective and therapeutic immunity in rabbits. Recent studies have shown that peptides delivered by the mucosal routes also stimulate local and systemic immune responses. Since mucosal delivery is easier to administer and more cost-effective when compared to gene-gun delivery, we were interested to learn whether mucosally delivered peptides would prime protective immunity comparable to that of gene-gun-delivered DNA in rabbits. Our newly developed HLA-A2.1 transgenic rabbit model was used to test the hypothesis. We chose an HLA-A2.1 restricted cottontail rabbit papillomavirus (CRPV) E1 epitope (E1/303-311, MLQEKPFQL) for the peptide immunization studies because it provided complete protection when used as a DNA vaccine. Adjuvant has been widely used to boost immunity for vaccines. In this study, three adjuvants reported to be effective for rabbits (TT helper motif, PADRE and CpG2007) were tested with the peptide vaccine. Peptide alone or fused to TT helper or PADRE to create chimeric peptides was delivered by two mucosal routes (ocular and intranasal) together. Partial protection was found in HLA-A2.1 transgenic rabbits when peptide was delivered mucosally in the presence of adjuvant. When a subsequent booster of a half-dose of the corresponding DNA vaccine was delivered, complete protections were achieved. We conclude that mucosal peptide immunization can be combined with a single DNA vaccination to provide strong protective immunity in rabbits.

UR - http://www.scopus.com/inward/record.url?scp=77953137288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953137288&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.03.015

DO - 10.1016/j.vaccine.2010.03.015

M3 - Article

C2 - 20332046

AN - SCOPUS:77953137288

VL - 28

SP - 3706

EP - 3713

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 21

ER -